Chemotherapy News and Research

RSS

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.

New Treatment Targets Tumor Microenvironment to Fight Breast Cancer

"Build your enemy a golden bridge to retreat across" is a piece of advice offered by Sun Tzu in his ancient military treatise, The Art of War. It turns out that cancerous growths adopt this strategy in their battle against the immune system.

24 Dec 2024

A revolutionary antibody approach to fight cancer by restoring cellular fitness

Ovarian cancer cells exploit cell competition by altering Flower protein isoforms in stromal cells, promoting tumor survival and potential therapeutic targets.

18 Dec 2024

Advancements in Cell-Penetrating Antibodies Open New Avenues in Cancer Therapy

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, 2024, titled "Advancements in cell-penetrating monoclonal antibody treatment."

12 Dec 2024

"Molecular GPS" Developed to Guide Immune Cells into the Brain and Kill Tumors

Researchers have found a way to program immune cells to attack glioblastoma and treat the inflammation of multiple sclerosis in mice.

6 Dec 2024

Stanford Researchers Develop New Approach to Make Cancer Cells Self-Destruct

Our bodies divest themselves of 60 billion cells every day through a natural process of cell culling and turnover called apoptosis.

28 Nov 2024

Single-Cell Analysis Sheds Light on Leukemia Cell Heterogeneity

Chromosomal instability plays a crucial role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM and the European Molecular Biology Laboratory (EMBL) used state-of-the-art single-cell analysis methods to analyze the cellular heterogeneity of a specific form of acute myeloid leukemia.

26 Nov 2024

Versatile Molecule with a New Role in Genome Maintenance

A multi-institutional team of researchers from the Georgia Institute of Technology has uncovered a hitherto unidentified function for RNA.

22 Nov 2024

Immunotherapy Advances: CAR T Cells Targeting GD2 Offer Hope for Glioma Patients

Findings suggest GD2-specific CAR T-cell therapy is a viable option for H3K27M-mutant gliomas, with significant tumor shrinkage and clinical benefits observed.

22 Nov 2024

Molecule Found to Aid Intestinal Healing and Prevent Tumor Growth in Colorectal Cancer

Researchers at Karolinska Institutet have found a molecule that can both help the intestines to heal after damage and suppress tumor growth in colorectal cancer.

21 Nov 2024

A Closer Look at CAR T-Cell Therapy — Successes, Challenges, And Future

Chimeric antigen receptor T-cell therapy enhances immune response against cancer, with promising results in hematological malignancies and ongoing advancements.

13 Nov 2024

Study Uncovers Mechanism Behind B-Cell Maturation in Leukemia

Over four hundred people, 80% of them being children under 14 years old, will be diagnosed with B-cell Acute Lymphoblastic Leukaemia (B-ALL) next year in Spain, according to the latest projections from the Spanish network of cancer registries (REDECAN).

23 Oct 2024

Researchers Develop Highly Selective SARS-CoV-2 Mpro Inhibitors

New research from The Wistar Institute's Salvino lab -; led by professor Joseph Salvino, Ph.D. -; has identified a novel series of SARS-CoV-2 Mpro inhibitors that may lead to potential new COVID-19 treatments that, according to preclinical testing, effectively inhibits COVID-19 and synergizes with existing anti-COVID therapies.

9 Oct 2024

High-throughput screening identifies potential drugs for low-grade serous ovarian cancer

In a recent study, researchers used high-throughput drug screening to identify potential therapeutic targets and novel treatments for low-grade serous ovarian cancer (LGSOC), offering hope for more effective and personalized therapies.

26 Sep 2024

Neutron Scattering Reveals Enzyme Secrets

Scientists have uncovered amazing information about the role of an enzyme that could assist in the development of drugs for aggressive cancers in just two neutron experiments.

25 Sep 2024

Breakthrough Nanoparticle Therapy Boosts Immune Response Against Aggressive Pancreatic Cancer

Innovative use of lipid nanoparticles to deliver immune agonists shows promise in activating anti-tumor immunity in pancreatic ductal adenocarcinoma models.

9 Sep 2024

Researchers Uncover Hundreds of New Potential Cancer Driver Genes

Researchers at the Centre for Genomic Regulation (CRG) have discovered hundreds of potential new cancer driver genes.

4 Sep 2024

European Commission Approves Erdafitinib for Advanced Urothelial Carcinoma

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved BALVERSA®▼(erdafitinib) as a once-daily oral monotherapy for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (mUC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations who have previously received at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor in the unresectable or metastatic treatment setting.

30 Aug 2024

RYBREVANT Receives EC Nod for Advanced Lung Cancer Treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II extension of indication for RYBREVANT®▼ (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

30 Aug 2024

Researchers on the Brink of a Scientific Breakthrough in Cancer Treatment

By figuring out how the body’s immune system targets diseased cells, a multinational team of scientists is on the cusp of a breakthrough in the fight against cancer.

29 Aug 2024

Study Utilizes Flow Cytometry and Advanced Transcriptomics to Reveal Age-Related Defects in Thymic Regeneration

Research identifies two states of age-associated thymic epithelial cells, linking thymic degeneration to aging and injury, impacting immune system function.

26 Aug 2024